ZYME Zymeworks Inc.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Date	Price Target	Rating	Analyst
5/20/2025		Buy	TD Cowen
12/16/2024	$18.00	Neutral → Overweight	Analyst
11/7/2024	$10.00 → $25.00	Market Perform → Outperform	Leerink Partners
11/1/2024	$12.00	Overweight → Equal Weight	Wells Fargo
3/21/2023	$12.00	Overweight	Wells Fargo
1/4/2023	$10.00 → $8.00	Neutral	H.C. Wainwright
12/20/2022	$7.70 → $11.00	Hold → Buy	Jefferies
11/1/2022	$40.00 → $8.00	Buy → Neutral	H.C. Wainwright
10/21/2022	$8.00	Outperform → Mkt Perform	SVB Leerink
10/4/2022	$45.00 → $9.00	Overweight	Wells Fargo

Zymeworks Inc.

Peers

Recent Analyst Ratings for Zymeworks Inc.

Zymeworks Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Ecor1 Capital, Llc bought $635,586 worth of shares (55,421 units at $11.47) (SEC Form 4)

Director Ecor1 Capital, Llc bought $1,456,408 worth of shares (128,713 units at $11.32) (SEC Form 4)

Director Ecor1 Capital, Llc bought $3,623,970 worth of shares (317,208 units at $11.42) (SEC Form 4)

Director Ecor1 Capital, Llc bought $1,497,322 worth of shares (127,415 units at $11.75) (SEC Form 4)

Director Ecor1 Capital, Llc bought $1,227,309 worth of shares (97,349 units at $12.61) (SEC Form 4)

Director Ecor1 Capital, Llc bought $1,643,248 worth of shares (127,198 units at $12.92) (SEC Form 4)

Director Ecor1 Capital, Llc bought $2,866,553 worth of shares (228,463 units at $12.55) (SEC Form 4)

Director Ecor1 Capital, Llc bought $13,120,914 worth of shares (1,081,980 units at $12.13) (SEC Form 4)

Director Ecor1 Capital, Llc bought $1,963,538 worth of shares (141,429 units at $13.88) (SEC Form 4)

Director Ecor1 Capital, Llc bought $2,278,811 worth of shares (167,654 units at $13.59) (SEC Form 4)